GLP1R and breast carcinoma: But they are only a preclinical study, not based on human or other primates.[32,33] Moreover, several meta-analysis suggested that GLP-1 receptor agonists did not associate with the incidence of pancreatic, thyroid, and breast cancers.[34–38]